These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 29929545)

  • 1. Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer.
    Liang H; Zhao X; Wang C; Sun J; Chen Y; Wang G; Fang L; Yang R; Yu M; Gu Y; Shan H
    Mol Cancer; 2018 Jun; 17(1):96. PubMed ID: 29929545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression.
    Liang H; Yu T; Han Y; Jiang H; Wang C; You T; Zhao X; Shan H; Yang R; Yang L; Shan H; Gu Y
    Mol Cancer; 2018 Aug; 17(1):119. PubMed ID: 30098599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. lncRNA AC005224.4/miR-140-3p/SNAI2 regulating axis facilitates the invasion and metastasis of ovarian cancer through epithelial-mesenchymal transition.
    Xiong T; Wang Y; Zhang Y; Yuan J; Zhu C; Jiang W
    Chin Med J (Engl); 2023 May; 136(9):1098-1110. PubMed ID: 36939239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical significance and biological function of lncRNA SOCAR in serous ovarian carcinoma.
    Guo Q; Wang L; Zhu L; Lu X; Song Y; Sun J; Wu Z; Shi J; Wang Z; Zhou X
    Gene; 2019 Sep; 713():143969. PubMed ID: 31299360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.
    Yang D; Sun Y; Hu L; Zheng H; Ji P; Pecot CV; Zhao Y; Reynolds S; Cheng H; Rupaimoole R; Cogdell D; Nykter M; Broaddus R; Rodriguez-Aguayo C; Lopez-Berestein G; Liu J; Shmulevich I; Sood AK; Chen K; Zhang W
    Cancer Cell; 2013 Feb; 23(2):186-99. PubMed ID: 23410973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L; Wang H; Li P
    Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.
    Braga EA; Fridman MV; Moscovtsev AA; Filippova EA; Dmitriev AA; Kushlinskii NE
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long Non-coding RNA
    Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT
    Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA-CTS promotes metastasis and epithelial-to-mesenchymal transition through regulating miR-505/ZEB2 axis in cervical cancer.
    Feng S; Liu W; Bai X; Pan W; Jia Z; Zhang S; Zhu Y; Tan W
    Cancer Lett; 2019 Nov; 465():105-117. PubMed ID: 31499118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene microarray analysis of lncRNA and mRNA expression profiles in patients with high‑grade ovarian serous cancer.
    Lou Y; Jiang H; Cui Z; Wang X; Wang L; Han Y
    Int J Mol Med; 2018 Jul; 42(1):91-104. PubMed ID: 29577163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of ovarian cancer cell secretome during epithelial to mesenchymal transition reveals a protein signature associated with advanced stages of ovarian tumors.
    Lanfredi GP; Thomé CH; Ferreira GA; Silvestrini VC; Masson AP; Vargas AP; Grassi ML; Poersch A; Candido Dos Reis FJ; Faça VM
    Biochim Biophys Acta Proteins Proteom; 2021 Jun; 1869(6):140623. PubMed ID: 33607274
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Terashima M; Ishimura A; Wanna-Udom S; Suzuki T
    J Biol Chem; 2018 Nov; 293(47):18016-18030. PubMed ID: 30262664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A PTAL-miR-101-FN1 Axis Promotes EMT and Invasion-Metastasis in Serous Ovarian Cancer.
    Liang H; Yu M; Yang R; Zhang L; Zhang L; Zhu D; Luo H; Hong Y; Yu T; Sun J; Shan H; Gu Y
    Mol Ther Oncolytics; 2020 Mar; 16():53-62. PubMed ID: 31930166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA FLVCR1-AS1 mediates miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in ovarian cancer.
    Yan H; Li H; Silva MA; Guan Y; Yang L; Zhu L; Zhang Z; Li G; Ren C
    J Exp Clin Cancer Res; 2019 Aug; 38(1):356. PubMed ID: 31412903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer.
    Li H; Wang X; Wen C; Huo Z; Wang W; Zhan Q; Cheng D; Chen H; Deng X; Peng C; Shen B
    Mol Cancer; 2017 Nov; 16(1):169. PubMed ID: 29121972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. lncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA.
    Lv M; Zhong Z; Huang M; Tian Q; Jiang R; Chen J
    Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1887-1899. PubMed ID: 28779971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.
    Dwivedi SK; Mustafi SB; Mangala LS; Jiang D; Pradeep S; Rodriguez-Aguayo C; Ling H; Ivan C; Mukherjee P; Calin GA; Lopez-Berestein G; Sood AK; Bhattacharya R
    Oncotarget; 2016 Mar; 7(12):15093-104. PubMed ID: 26918603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNAs AC026904.1 and UCA1: a "one-two punch" for TGF-β-induced SNAI2 activation and epithelial-mesenchymal transition in breast cancer.
    Li GY; Wang W; Sun JY; Xin B; Zhang X; Wang T; Zhang QF; Yao LB; Han H; Fan DM; Yang AG; Jia LT; Wang L
    Theranostics; 2018; 8(10):2846-2861. PubMed ID: 29774079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer.
    Tung CH; Kuo LW; Huang MF; Wu YY; Tsai YT; Wu JE; Hsu KF; Chen YL; Hong TM
    Oncogene; 2020 Jan; 39(4):862-876. PubMed ID: 31570789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis.
    Liu F; Zhang G; Lv S; Wen X; Liu P
    J Cell Biochem; 2019 Aug; 120(8):12618-12627. PubMed ID: 30834603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.